Lutathera (lutetium Lu 177 dotatate) has won US FDA approval to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The peptide receptor radionuclide therapy became the first product to be approved in the US this year, and the first radiopharmaceutical approved by the FDA to treat GEP-NETs, just four days after Novartis AG completed its purchase of the drug's developer, radiopharmaceutical specialist Advanced Accelerator Applications SA.
An Advanced Accelerator Applications spokeswoman said that the list price for Lutathera, which is classified as an orphan drug in...







